Quick Takeaways
- This page summarizes Karen L. Smith's Form 4 filing for Skye Bioscience, Inc. (SKYE).
- 1 reported transaction and 1 derivative row are listed below.
- Filing timestamp: 26 Feb 2025, 17:45.
Karen L. Smith - 24 Feb 2025 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)
- Role
- Director
- Signature
- /s/ Kaitlyn Arsenault, as Attorney-in-Fact
- Issuer symbol
- SKYE
- Transactions as of
- 24 Feb 2025
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 26 Feb 2025, 17:45:16 UTC
- Previous filing
- 25 Nov 2024
- Next filing
- 16 Jun 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Karen L. Smith filed Form 4 for Skye Bioscience, Inc. (SKYE) on 26 Feb 2025."
What Changed
- Previous filing in this sequence was filed on 25 Nov 2024.
- Current net transaction value: $0.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Official SEC Source
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SKYE | Stock Option (Right to Buy) | Award | $0 | +35,000 | $0.000000 | 35,000 | 24 Feb 2025 | Common Stock | 35,000 | $2.89 | Direct | F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The stock option vests in equal monthly installments over the one year period beginning February 21, 2025. |